Market Overview

UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

Related AMRN
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
FDA Approvals And Changes For The Week Ending February 14, 2014

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on Amarin (NASDAQ: AMRN), but lowered the price target from $24.00 to $20.00.

In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”

Amarin closed on Thursday at $5.31.

Posted-In: Jefferies Thomas WeiAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free